These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37766666)

  • 1. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
    Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
    Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis.
    Stabellini N; Cao L; Towe CW; Luo X; Amin AL; Montero AJ
    Front Oncol; 2023; 13():1115208. PubMed ID: 37168373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
    Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
    Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database.
    Ashok Kumar P; Wang D; Huang D; Sivapiragasam A
    JCO Precis Oncol; 2024 Mar; 8():e2300390. PubMed ID: 38564683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
    Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
    Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.
    Yaghi M; Bilani N; Dominguez B; Jabbal IS; Rivera C; Bou Zerdan M; Li H; Saravia D; Stone E; Nahleh Z
    Breast; 2022 Aug; 64():112-120. PubMed ID: 35640346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
    N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
    Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer.
    White MJ; Kolbow M; Prathibha S; Praska C; Ankeny JS; LaRocca CJ; Jensen EH; Tuttle TM; Hui JYC; Marmor S
    Breast Cancer Res Treat; 2023 Apr; 198(2):309-319. PubMed ID: 36692668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
    Weiser R; Haque W; Polychronopoulou E; Hatch SS; Kuo YF; Gradishar WJ; Klimberg VS
    Breast Cancer Res Treat; 2021 Feb; 185(3):667-676. PubMed ID: 33070279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
    Nguy S; Wu SP; Oh C; Gerber NK
    Breast Cancer Res Treat; 2021 Jun; 187(3):815-830. PubMed ID: 33590386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL; Dhesy-Thind S; Rastogi P; Alba E; Delaloge S; Martin M; Kelly CM; Ruiz-Borrego M; Gil-Gil M; Arce-Salinas CH; Brain EGC; Lee ES; Pierga JY; Bermejo B; Ramos-Vazquez M; Jung KH; Ferrero JM; Schott AF; Shak S; Sharma P; Lew DL; Miao J; Tripathy D; Pusztai L; Hortobagyi GN
    N Engl J Med; 2021 Dec; 385(25):2336-2347. PubMed ID: 34914339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
    Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
    JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.